Lymphocyte gene expression data from moderate stage HD patients and controls
Highly quantitative biomarkers of neurodegenerative disease remain an important need in the urgent quest for disease modifying therapies. For Huntington's disease (HD), a genetic test is available (trait marker), but necessary state markers are still in development. In this report, we describe a large battery of transcriptomic tests explored as state biomarker candidates. In an attempt to exploit the known neuroinflammatory and transcriptional perturbations of disease, we measured relevant mRNAs...
Provenance — who produced it, who reused it
Linked to 11 papers in the literature. Roles are inferred factual signals (who deposited the data vs who reused it), with counts — never a judgement about any author.
- Down-weighting overlapping genes improves gene set analysis 2012 · 162 cites
- Comparative study on gene set and pathway topology-based enrichm... 2015 · 91 cites
- A distinct p53 target gene set predicts for response to the sele... 2015 · 87 cites
- Ranking metrics in gene set enrichment analysis: do they matter? 2017 · 80 cites
7 further papers cite this accession but reuse could not be confirmed.
Deep data QC
metadata only · no data-level QC for this typeStandardized, field-standard QC computed by touching the data — every metric states how it was obtained
No quantitative QC rubric exists for this data type yet, so it is deliberately left unscored — this is an honest "not applicable", not a poor rating.
measured = computed from the data · extrapolated/reported = derived or from the repository · dq-1.0 · provisional — verify independently